Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Cystic Fibrosis Market

ID: MRFR/Pharma/1293-CR
62 Pages
Nidhi Mandole
Last Updated: April 02, 2026

Cystic Fibrosis Market Research Report Information By Treatment Method (Medication and Devices), By Route of Administration (Oral and Inhaled), By Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, Antibiotics and CFTR modulators), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Cystic Fibrosis Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Treatment Method (USD Billion)
  49.     4.1.1 Medication
  50.     4.1.2 Devices
  51.   4.2 Healthcare, BY Route of Administration (USD Billion)
  52.     4.2.1 Oral
  53.     4.2.2 Inhaled
  54.   4.3 Healthcare, BY Drug Class (USD Billion)
  55.     4.3.1 Pancreatic Enzyme Supplements
  56.     4.3.2 Mucolytic
  57.     4.3.3 Bronchodilators
  58.     4.3.4 Antibiotics
  59.     4.3.5 CFTR modulators
  60.   4.4 Healthcare, BY Region (USD Billion)
  61.     4.4.1 North America
  62.       4.4.1.1 US
  63.       4.4.1.2 Canada
  64.     4.4.2 Europe
  65.       4.4.2.1 Germany
  66.       4.4.2.2 UK
  67.       4.4.2.3 France
  68.       4.4.2.4 Russia
  69.       4.4.2.5 Italy
  70.       4.4.2.6 Spain
  71.       4.4.2.7 Rest of Europe
  72.     4.4.3 APAC
  73.       4.4.3.1 China
  74.       4.4.3.2 India
  75.       4.4.3.3 Japan
  76.       4.4.3.4 South Korea
  77.       4.4.3.5 Malaysia
  78.       4.4.3.6 Thailand
  79.       4.4.3.7 Indonesia
  80.       4.4.3.8 Rest of APAC
  81.     4.4.4 South America
  82.       4.4.4.1 Brazil
  83.       4.4.4.2 Mexico
  84.       4.4.4.3 Argentina
  85.       4.4.4.4 Rest of South America
  86.     4.4.5 MEA
  87.       4.4.5.1 GCC Countries
  88.       4.4.5.2 South Africa
  89.       4.4.5.3 Rest of MEA
  90. 5 SECTION V: COMPETITIVE ANALYSIS
  91.   5.1 Competitive Landscape
  92.     5.1.1 Overview
  93.     5.1.2 Competitive Analysis
  94.     5.1.3 Market share Analysis
  95.     5.1.4 Major Growth Strategy in the Healthcare
  96.     5.1.5 Competitive Benchmarking
  97.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  98.     5.1.7 Key developments and growth strategies
  99.       5.1.7.1 New Product Launch/Service Deployment
  100.       5.1.7.2 Merger & Acquisitions
  101.       5.1.7.3 Joint Ventures
  102.     5.1.8 Major Players Financial Matrix
  103.       5.1.8.1 Sales and Operating Income
  104.       5.1.8.2 Major Players R&D Expenditure. 2023
  105.   5.2 Company Profiles
  106.     5.2.1 Vertex Pharmaceuticals (US)
  107.       5.2.1.1 Financial Overview
  108.       5.2.1.2 Products Offered
  109.       5.2.1.3 Key Developments
  110.       5.2.1.4 SWOT Analysis
  111.       5.2.1.5 Key Strategies
  112.     5.2.2 AbbVie (US)
  113.       5.2.2.1 Financial Overview
  114.       5.2.2.2 Products Offered
  115.       5.2.2.3 Key Developments
  116.       5.2.2.4 SWOT Analysis
  117.       5.2.2.5 Key Strategies
  118.     5.2.3 Gilead Sciences (US)
  119.       5.2.3.1 Financial Overview
  120.       5.2.3.2 Products Offered
  121.       5.2.3.3 Key Developments
  122.       5.2.3.4 SWOT Analysis
  123.       5.2.3.5 Key Strategies
  124.     5.2.4 Novartis (CH)
  125.       5.2.4.1 Financial Overview
  126.       5.2.4.2 Products Offered
  127.       5.2.4.3 Key Developments
  128.       5.2.4.4 SWOT Analysis
  129.       5.2.4.5 Key Strategies
  130.     5.2.5 Roche (CH)
  131.       5.2.5.1 Financial Overview
  132.       5.2.5.2 Products Offered
  133.       5.2.5.3 Key Developments
  134.       5.2.5.4 SWOT Analysis
  135.       5.2.5.5 Key Strategies
  136.     5.2.6 Teva Pharmaceutical Industries (IL)
  137.       5.2.6.1 Financial Overview
  138.       5.2.6.2 Products Offered
  139.       5.2.6.3 Key Developments
  140.       5.2.6.4 SWOT Analysis
  141.       5.2.6.5 Key Strategies
  142.     5.2.7 Chiesi Farmaceutici (IT)
  143.       5.2.7.1 Financial Overview
  144.       5.2.7.2 Products Offered
  145.       5.2.7.3 Key Developments
  146.       5.2.7.4 SWOT Analysis
  147.       5.2.7.5 Key Strategies
  148.     5.2.8 MediGene AG (DE)
  149.       5.2.8.1 Financial Overview
  150.       5.2.8.2 Products Offered
  151.       5.2.8.3 Key Developments
  152.       5.2.8.4 SWOT Analysis
  153.       5.2.8.5 Key Strategies
  154.   5.3 Appendix
  155.     5.3.1 References
  156.     5.3.2 Related Reports
  157. 6 LIST OF FIGURES
  158.   6.1 MARKET SYNOPSIS
  159.   6.2 NORTH AMERICA MARKET ANALYSIS
  160.   6.3 US MARKET ANALYSIS BY TREATMENT METHOD
  161.   6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  162.   6.5 US MARKET ANALYSIS BY DRUG CLASS
  163.   6.6 CANADA MARKET ANALYSIS BY TREATMENT METHOD
  164.   6.7 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  165.   6.8 CANADA MARKET ANALYSIS BY DRUG CLASS
  166.   6.9 EUROPE MARKET ANALYSIS
  167.   6.10 GERMANY MARKET ANALYSIS BY TREATMENT METHOD
  168.   6.11 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  169.   6.12 GERMANY MARKET ANALYSIS BY DRUG CLASS
  170.   6.13 UK MARKET ANALYSIS BY TREATMENT METHOD
  171.   6.14 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  172.   6.15 UK MARKET ANALYSIS BY DRUG CLASS
  173.   6.16 FRANCE MARKET ANALYSIS BY TREATMENT METHOD
  174.   6.17 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  175.   6.18 FRANCE MARKET ANALYSIS BY DRUG CLASS
  176.   6.19 RUSSIA MARKET ANALYSIS BY TREATMENT METHOD
  177.   6.20 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  178.   6.21 RUSSIA MARKET ANALYSIS BY DRUG CLASS
  179.   6.22 ITALY MARKET ANALYSIS BY TREATMENT METHOD
  180.   6.23 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  181.   6.24 ITALY MARKET ANALYSIS BY DRUG CLASS
  182.   6.25 SPAIN MARKET ANALYSIS BY TREATMENT METHOD
  183.   6.26 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  184.   6.27 SPAIN MARKET ANALYSIS BY DRUG CLASS
  185.   6.28 REST OF EUROPE MARKET ANALYSIS BY TREATMENT METHOD
  186.   6.29 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  187.   6.30 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
  188.   6.31 APAC MARKET ANALYSIS
  189.   6.32 CHINA MARKET ANALYSIS BY TREATMENT METHOD
  190.   6.33 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  191.   6.34 CHINA MARKET ANALYSIS BY DRUG CLASS
  192.   6.35 INDIA MARKET ANALYSIS BY TREATMENT METHOD
  193.   6.36 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  194.   6.37 INDIA MARKET ANALYSIS BY DRUG CLASS
  195.   6.38 JAPAN MARKET ANALYSIS BY TREATMENT METHOD
  196.   6.39 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  197.   6.40 JAPAN MARKET ANALYSIS BY DRUG CLASS
  198.   6.41 SOUTH KOREA MARKET ANALYSIS BY TREATMENT METHOD
  199.   6.42 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  200.   6.43 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
  201.   6.44 MALAYSIA MARKET ANALYSIS BY TREATMENT METHOD
  202.   6.45 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  203.   6.46 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
  204.   6.47 THAILAND MARKET ANALYSIS BY TREATMENT METHOD
  205.   6.48 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  206.   6.49 THAILAND MARKET ANALYSIS BY DRUG CLASS
  207.   6.50 INDONESIA MARKET ANALYSIS BY TREATMENT METHOD
  208.   6.51 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  209.   6.52 INDONESIA MARKET ANALYSIS BY DRUG CLASS
  210.   6.53 REST OF APAC MARKET ANALYSIS BY TREATMENT METHOD
  211.   6.54 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  212.   6.55 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
  213.   6.56 SOUTH AMERICA MARKET ANALYSIS
  214.   6.57 BRAZIL MARKET ANALYSIS BY TREATMENT METHOD
  215.   6.58 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  216.   6.59 BRAZIL MARKET ANALYSIS BY DRUG CLASS
  217.   6.60 MEXICO MARKET ANALYSIS BY TREATMENT METHOD
  218.   6.61 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  219.   6.62 MEXICO MARKET ANALYSIS BY DRUG CLASS
  220.   6.63 ARGENTINA MARKET ANALYSIS BY TREATMENT METHOD
  221.   6.64 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  222.   6.65 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
  223.   6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT METHOD
  224.   6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  225.   6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
  226.   6.69 MEA MARKET ANALYSIS
  227.   6.70 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT METHOD
  228.   6.71 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  229.   6.72 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
  230.   6.73 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT METHOD
  231.   6.74 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  232.   6.75 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
  233.   6.76 REST OF MEA MARKET ANALYSIS BY TREATMENT METHOD
  234.   6.77 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  235.   6.78 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
  236.   6.79 KEY BUYING CRITERIA OF HEALTHCARE
  237.   6.80 RESEARCH PROCESS OF MRFR
  238.   6.81 DRO ANALYSIS OF HEALTHCARE
  239.   6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  240.   6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  241.   6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
  242.   6.85 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE)
  243.   6.86 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Billion)
  244.   6.87 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  245.   6.88 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  246.   6.89 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
  247.   6.90 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
  248.   6.91 BENCHMARKING OF MAJOR COMPETITORS
  249. 7 LIST OF TABLES
  250.   7.1 LIST OF ASSUMPTIONS
  251.     7.1.1
  252.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  253.     7.2.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  254.     7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  255.     7.2.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  256.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  257.     7.3.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  258.     7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  259.     7.3.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  260.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  261.     7.4.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  262.     7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  263.     7.4.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  264.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  265.     7.5.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  266.     7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  267.     7.5.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  268.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  269.     7.6.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  270.     7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  271.     7.6.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  272.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  273.     7.7.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  274.     7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  275.     7.7.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  276.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  277.     7.8.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  278.     7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  279.     7.8.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  280.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  281.     7.9.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  282.     7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  283.     7.9.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  284.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  285.     7.10.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  286.     7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  287.     7.10.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  288.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  289.     7.11.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  290.     7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  291.     7.11.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  292.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  293.     7.12.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  294.     7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  295.     7.12.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  296.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  297.     7.13.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  298.     7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  299.     7.13.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  300.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  301.     7.14.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  302.     7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  303.     7.14.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  304.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  305.     7.15.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  306.     7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  307.     7.15.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  308.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  309.     7.16.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  310.     7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  311.     7.16.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  312.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  313.     7.17.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  314.     7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  315.     7.17.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  316.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  317.     7.18.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  318.     7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  319.     7.18.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  320.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  321.     7.19.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  322.     7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  323.     7.19.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  324.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  325.     7.20.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  326.     7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  327.     7.20.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  328.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  329.     7.21.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  330.     7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  331.     7.21.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  332.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  333.     7.22.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  334.     7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  335.     7.22.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  336.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  337.     7.23.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  338.     7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  339.     7.23.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  340.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  341.     7.24.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  342.     7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  343.     7.24.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  344.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  345.     7.25.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  346.     7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  347.     7.25.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  348.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  349.     7.26.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  350.     7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  351.     7.26.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  352.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  353.     7.27.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  354.     7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  355.     7.27.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  356.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  357.     7.28.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  358.     7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  359.     7.28.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  360.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  361.     7.29.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  362.     7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  363.     7.29.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  364.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  365.     7.30.1 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  366.     7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  367.     7.30.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  368.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  369.     7.31.1
  370.   7.32 ACQUISITION/PARTNERSHIP
  371.     7.32.1

Healthcare Market Segmentation

Healthcare By Treatment Method (USD Billion, 2025-2035)

  • Medication
  • Devices

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Inhaled

Healthcare By Drug Class (USD Billion, 2025-2035)

  • Pancreatic Enzyme Supplements
  • Mucolytic
  • Bronchodilators
  • Antibiotics
  • CFTR modulators

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions